Articles written by Vandana Singh - Benzinga

Specialty Pharma Amphastar Stock Falls On Lower Than Expected Q4 Earnings, Analyst Sees Competitive Headwinds

Amphastar's Q4 sales grew 20% to $186.5M, missing estimates. Primatene MIST surpassed $100M in annual sales, while Baqsimi saw strong growth.

Analyst Downgrades LAVA Therapeutics, Sees Pipeline Overhang

LAVA Therapeutics reviews strategic options amid cost cuts. HC Wainwright downgrades stock, citing uncertainties over LAVA-1266 and possible business shifts.

ANI Pharmaceuticals Expects Strong Start To 2025, On Back Of Cortrophin Gel And Generics, Lifts Annual Forecast

ANI Pharmaceuticals beat Q4 estimates with strong sales growth and raised its 2025 revenue and EPS outlook, driven by Cortrophin Gel and brand expansion.

Healthcare Logistics Firm Owens & Minor Reports Better-Than-Expected Q4 Earnings, Plans To Repurchase $100 Million In Shares

Owens & Minor beat Q4 EPS and revenue estimates, announced a $100M buyback, and provided 2025 guidance, projecting double-digit adjusted EBITDA growth.

Eli Lilly Doubles Capital Spending On US Drug Manufacturing With $50 Billion Target (CORRECTED)

Eli Lilly is investing over $50 billion in U.S. manufacturing, adding four new sites to boost domestic medicine production and create thousands of jobs.

Generic Drugmaker Amneal Clocks Mixed Q4 Earnings, Plans Expansion In High-Growth Areas Like Weight Loss Products, Biosimilars

Amneal Pharmaceuticals' Q4 sales rose 18% to $730.52M, surpassing estimates, while adjusted EPS missed. The company forecasts up to $3.1B in 2025 revenue.

Psychedelics-Focused Compass Pathways Has Established Itself As 'Credible CNS Biotechnology Company,' Analyst Says

Compass Pathways gains Stifel's Buy rating as its COMP360 psilocybin treatment advances in Phase 3 trials. Key depression study data expected in 2025-2026.

NovoCure Reports Wider Than Expected Q4 Loss Despite 21% Jump In Sales, Expects Product Enhancements To Hit Gross Margin In 2025

NovoCure's Q4 revenue rose 21% to $161.27M, surpassing expectations, while its loss widened. Annual sales hit $605M, fueled by Optune Gio's expansion.

Autoimmune Disease-Focused Aurinia Pharmaceuticals Reports Quarterly Profit, Revenue Outlook Below Expectations

Aurinia Pharmaceuticals reported Q4 earnings of 1 cent per share, beating estimates, with LUPKYNIS sales up 36%.

Viatris Stock Tumbles On Q4 Earnings Miss, FDA Warning Clouds 2025 Outlook

Viatris missed Q4 estimates with an 8% revenue decline. 2025 guidance falls short as FDA import alert hits sales. Share repurchases prioritized.

GoodRx Reports Mixed Q4: Pharma Strength Amid Subscription Decline, Sluggish Prescription Sales

GoodRx reported Q4 revenue of $198.6M, missing expectations. 2025 guidance projects $810M–$840M revenue and adjusted EBITDA of $270M–$286M.

Cronos Q4 Sales Jump 27% On Higher Cannabis Flower And Extract Sales, Reports Improved Profitability

Cronos' Q4 sales rose to $30.3M but missed estimates. Gross profit surged, and adjusted EBITDA loss improved as the company eyes long-term growth.

Teleflex Hits 52-Week Low On Plan To Split Into Two Companies, Reports Mixed Q4 Earnings

Teleflex to separate into two companies by mid-2026 and acquire Biotronik's Vascular Intervention unit for €760 million. CFO Thomas Powell to retire in April.

Novavax Reports Smaller Q4 Loss, Shifts Focus From Commercializing COVID-19 Vaccine To Maximize Value

Novavax reported Q4 sales of $88.31 million, beating estimates despite a decline. The company shifts focus to partnerships and expects up to $350 million in 2025 revenue.

Sensodyne Toothpaste Maker Haleon Expects Profit To Be Weighted Towards Second Half Of 2025

Haleon posted £11.23B in FY24 revenue, with 5% organic growth. 2025 guidance expects 4-6% organic growth, with profit gains weighted to the second half.

What's Going On With MedTech Focused Inogen Stock On Wednesday?

Inogen beat Q4 earnings and revenue estimates, citing strong B2B demand. Analysts see potential but flag supply challenges and restructuring risks.

Johnson & Johnson Sues Samsung Bioepis Over Alleged Biosimilar Agreement Breach For Its Flagship Psoriasis Drug

Janssen has sued Samsung Bioepis, alleging it violated a settlement agreement by authorizing an unauthorized Stelara® biosimilar, potentially harming market competition.

Novo Nordisk's Ozempic And Wegovy No Longer on FDA Shortage List, Faces Lawsuit Over Decision

A lawsuit challenges the FDA's decision to remove semaglutide from the shortage list, alleging it was arbitrary and harms patients who rely on compounded versions of the drug.

Court Dismisses Novartis Challenge To Medicare Drug Price Negotiation Program

A federal court rejected Novartis' legal challenge to the Medicare Drug Price Negotiation Program, ruling that it does not impose unconstitutional fines, takings, or compelled speech.

Madrigal Pharmaceuticals Stock Jumps On New Two-Year Data Showing Potential Benefit of Rezdiffra For Compensated Fatty Liver Cirrhosis

Madrigal's Rezdiffra showed significant liver stiffness reduction in MASH cirrhosis. The company also beat Q4 earnings and revenue expectations.